Asthma Clinical Trial
Official title:
Effects of Noninvasive Ventilation Compared to Salbutamol in Respiratory Mechanics and Lung Function of Asthmatics After Bronchoprovocation: Randomized Cross-over Trial
Asthma is a chronic inflammatory disease characterized by recurrent and reversible episodes of airway obstruction. Drug treatment usually includes inhaled corticosteroids and bronchial dilators, which often do not have adequate adherence. These acute episodes of bronchoconstriction can most often occur with hyperinflation and for decades the mechanisms that lead to hyperinflation have been studied, as well as increasingly modern ways of evaluating and treating these mechanisms. Noninvasive ventilation is increasingly occupying its space as a non-pharmacological resource in the treatment of asthma, initially as an adjunct in an attempt to help medication have its effect reached in the crisis, but this feature has been showing signs of having an even greater action which can even collaborate in reversing the crisis by not only giving time for pharmacological action. Recognizing these potential effects of this widely used resource and understanding its action on lung function and the reversal of exacerbation is part of this scientific process.
Asthma is a chronic inflammatory disease characterized by recurrent episodes of reversible
airway obstruction. The drug treatment typically includes inhaled steroids and bronco
dilators. These acute episodes of bronchoconstriction can, for the most part, attend with
hyperinflation, the hyperinflation and the consequent increase of functional residual
capacity (FRC) inspiratory muscle activation in phase before the expiratory lung elastic
equilibrium and rib cage.
Some studies reports the injury to respiratory function that causes acute hyperinflation with
a reduction of the contribution of the abdominal compartment and increased assistance from
the chest compartment, thereby reducing the efficiency mechanics of the diaphragm in response
to decreased your stamping area. As a result of this disadvantage and mechanics "reduction of
curvature" of the diaphragm expiratory muscle activation occurs in an attempt to restore the
original mechanics and thus your primary function.
Some studies have investigated the effects of bronchoconstriction in recruitment of the
respiratory muscles and respiratory mechanics of patients susceptible to asthma. As asthma
has distinct characteristics in crisis and in stable phase, testing of bronchial provocation
test have been part of the studies allowing assessment in different physiological conditions,
close to an acute condition without necessarily a crisis and insufficiency that would make it
really an assessment respiratory kinematics and the involvement of the thoracic and abdominal
compartments in each of these phases and mainly in front of any therapy.
Bronchial provocation tests are safe once they cause the release of endogenous mediators that
cause the bronchial smooth muscle contraction causing narrowing of the airway, but as your
sensitivity is reduced your action is completely reversed with use of bronchodilator and the
positive response to these tests that can be performed by exercise or inhaling hypertonic
solution 4.5% reflect a inflammation of the Airways.
The interest in the implementation of non-pharmacological therapies and especially the
knowledge of resources used often to relieve the overload of respiratory muscles in patients
with obstructive, since the Decade of 80, has been demonstrating that the use of expiratory
positive pressure can reduce muscle work and reduce the volume of expiratory reserve
contributing to deflation.
Most recently the bronchodilator effect of CPAP mediated by autonomic receptors stretch lung.
What we need to know is the effect of non-invasive ventilation with two levels of pressure
can in addition to trigger this neural reflex, can still promote a kinematics similar to
produced by bronchodilator seen through optoelectronics plethysmography (OEP).
The Optoelectronics Plethysmography (OEP) has made possible the exploitation of
Thoracoabdominal movement by magazines, reporting especially changes in total volume of the
chest wall during any intervention as the NIV.
The OEP is an innovative method of indirect measurement of pulmonary ventilation, and your
application can be used in different health conditions, like asthma and neuromuscular
diseases, with different protocols. Is a non-invasive method and measurement of non-ionizing
lung volumes, able to detect small movements of the chest wall during breathing through the
analysis of reflective markers attached to the chest wall of the individual; There is no need
to use mouthpiece, nasal clip or other connector of the equipment to the individual; the
calibration is fast and without the participation of the subject.
Since the NIV with bi-level pressure promotes a level of inspiratory pressure that increases
the expiratory ventilation and a stretch of lung receptors stimulates and bronchodilator
effect, the hypothesis of this study is that the thoracic and abdominal configuration and
improvement of pulmonary function after test of bronchial provocation test is considerable
with the NIV compared to bronchodilator. There are no studies in the literature that discuss
this subject under this optics of assessment.
The aim of this study is to evaluate the effects of the NIV in reversal of bronchial
provocation test and your potential bronchodilator effect compared to the gold standard
bronchodilator drug seen by thoracic and abdominal and lung function configuration.
2. General Purpose
To evaluate the responses of the thoracoabdominal configuration and the participation of the
thoracic and abdominal compartments in asthmatic patients before the bronchoprovocation test
and in response to pharmacological and non-pharmacological therapy.
2.1. Specific objectives
- To evaluate the abdominal thoracic configuration of adolescents and young adults with
stable asthma before and after bronchoprovocation
- To evaluate the effect of bronchodilator and NIV in the thoraco-abdominal configuration
3. Materials and Methods
3.1. Kind of study
This is a randomized, crossover clinical trial in which it will be performed in two visits
and evaluated the abdominal thoracic configuration before and after bronchoprovocation and
after bronchodilator and non-invasive ventilation (NIV) with two levels of pressure in
adolescents and young adults with asthma.
3.2. Ethical aspects
This study will be developed respecting the research standards involving human beings
(Resolution CNS 466/2012) of the National Health Council, was approved by the Research Ethics
Committee of the University Nove de Julho (2.130.007 / 2017). You will have your registration
done at clincaltrial.gov.
3.3. Place of study and sample
The study will be developed in the Multidisciplinary Laboratory of Movement, Optical
Electronic Plethysmography (OEP) and in the Functional Respiratory Evaluation Laboratory
located at the Latin American Memorial Campus of the University of Nove de Julho (UNINOVE),
at Francisco Matarazzo Avenue, 376, Barra Funda , Sao Paulo-SP.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
||
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|